🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
Based on the pervious data, aflibercept in combination with FOLFIRI is one ...
Status
Unknown
Location
Yonsei University
Start Date
2020-04-20
Trial ID
NCT04810585
Treatments Being Tested
This randomized phase II trial studies how well trametinib or combination c...
Status
Completed
Location
Alaska Breast Care and Surgery LLC
Start Date
2014-02
Trial ID
NCT02042443
Treatments Being Tested
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cell...
Status
Completed
Location
Ziekenhuis Network Antwerpen Middelheim
Start Date
1999-03
Trial ID
NCT00004150
Treatments Being Tested
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer...
Status
Completed
Location
Aurora Presbyterian Hospital
Start Date
1993-05-07
Trial ID
NCT00002514
Treatments Being Tested
Open label, randomized phase II study to evaluate efficacy and safety of CP...
Status
Withdrawn
Location
Hirschfeld Oncology
Start Date
2024-08-15
Trial ID
NCT06518538
Treatments Being Tested
The purpose of the study is to assess the safety and efficacy of OncoSil™ w...
Status
Active Not Recruiting
Location
Royal Adelaide Hospital
Start Date
2023-04-26
Trial ID
NCT05466799
Treatments Being Tested
This is a Phase III, randomized, two arms, double-blind (patient and assess...
Status
Completed
Location
Shafa Hospital
Start Date
2016-10-04
Trial ID
NCT03288987
Treatments Being Tested
It is expected that addition of anti-CD20 antibody - ofatumumab would enhan...
Status
Completed
Location
Dolnośląskie Centrum Transplantacji Komórkowych
Start Date
2011-11
Trial ID
NCT01481272
The goal of this Phase 3 clinical trial is to evaluate whether continuing c...
Status
Recruiting
Location
A.O.U. Ospedali Riuniti
Start Date
2025-10-01
Trial ID
NCT07389265
Erlotinib may stop the growth of tumor cells by blocking the enzymes necess...
Status
Completed
Location
Johns Hopkins University
Start Date
2003-06
Trial ID
NCT00060411
Treatments Being Tested